Sort
15,273 grants matching “antimicrobial resistance”
Modeling the Impact of Interventions to Reduce Typhoidal Salmonella Transmission in the Indo-Pacific.
$169,020Seth Ari Sim-Son Hoffman · Stanford University · K23 · FY2025 · AI
Rapid Detection of multiple sepsis pathogens
$169,001John F Davidson · Tangen Biosciences, Inc. · R43 · FY2017 · AI
Hepcidin and Anemia in Children: Mechanisms and Modifiers
$168,978Meredith Ann Atkinson · Johns Hopkins University · K23 · FY2014 · DK
Hepcidin and Anemia in Children: Mechanisms and Modifiers
$168,978Meredith Ann Atkinson · Johns Hopkins University · K23 · FY2015 · DK
Combatting Bladder Cancer by Inducing Epithelial Turnover
$168,894Soman N Abraham · Duke University · R21 · FY2020 · CA
Treatment of CGD with the PPAR-gamma agonist, pioglitazone, enhances phagocyte anti-inflammatory and antimicrobial responses
$168,825Donna L Bratton · National Jewish Health · U01 · FY2020 · AI
Treatment of CGD with the PPAR-gamma agonist, pioglitazone, enhances phagocyte anti-inflammatory and antimicrobial responses
$168,825Donna L Bratton · National Jewish Health · U01 · FY2019 · AI
AS THE WORLD POPULATION INCREASES AND WILD CAUGHT FISHERIES DECLINE, AQUACULTURE OFFERS A SUSTAINABLE SOLUTION TO INCREASED GLOBAL DEMANDS FOR QUALITY DIETARY PROTEIN SOURCES AND FOOD SECURITY. COMMERCIAL AQUACULTURE TYPICALLY USES INTENSIVE PRODUCTION PRACTICES FOR MAXIMAL POND PRODUCTIVITY. THESE PRACTICES OFTEN LEAD TO INCREASED FISH STRESS AND DISEASE OUTBREAKS THAT RESULT IN SIGNIFICANT ECONOMIC LOSSES AND ASSOCIATED NEGATIVE IMPACTS TO THE ENVIRONMENT. ANTIMICROBIALS (CHEMICALS AND ANTIBIOTICS) ARE THE PRIMARY THERAPEUTIC CHOICE HOWEVER >80% OF THESE DRUGS ARE ESTIMATED TO ENTER THE AQUACULTURE ENVIRONMENT INTACT. WHILE THE EXTENT OF ANTIMICROBIAL OVERUSE IN AQUATIC AND TERRESTRIAL ANIMAL FARMING IS HARD TO MEASURE, UNQUESTIONABLY THESE INDUSTRIES CONTRIBUTE SIGNIFICANTLY TO THE ANTIBIOTIC RESISTANCE PROBLEM THAT HAS REACHED GLOBAL EPIDEMIC PROPORTIONS AND THREATENS BOTH ANIMAL AND PUBLIC HEALTH. THIS PROJECT FOCUSES ON DELIVERING A NOVEL SOLUTION TO THE AQUACULTURE INDUSTRY IN TACKLING FARMED FISH DISEASE THAT LIMITS/MITIGATES THE USE OF TRADITIONALLY USED ANTIMICROBIALS. PROTEIN-BASED IMMUNOTHERAPEUTANTS OFFER A SIGNIFICANT PARADIGM SHIFT FROM ANTIBIOTICS AND CHEMICALS THAT PRESENTS THE POSSIBILITY OF LEVERAGING FOOD FISHES OWN NATURAL IMMUNE SYSTEM TO MANAGE AND PREVENT DISEASE IN AQUACULTURE.THIS PROJECT AIMS TO USE SUSTAINABLE PLANT-BASED BIOENGINEERING TECHNOLOGY TO PRODUCE A CATFISH IMMUNE PROTEIN THERAPY THAT WILL BE FUNCTIONAL AND STABLE IN THE AQUACULTURE SETTING. THIS RESEARCH WILL APPLY TECHNIQUES USED IN STUDYING THE IMMUNE SYSTEM OF OTHER ANIMALS TO PRODUCE CURRENTLY UNAVAILABLE DIAGNOSTIC TOOLS THAT CAN BE MORE BROADLY APPLIED TO FUTURE DEVELOPMENT OF THERAPEUTIC STRATEGIES FOR AQUACULTURE. THIS NOVEL CATFISH PROTEIN THERPEUTANT WILL BE TESTED FOR ACTIVITY IN CATFISH AS A PROOF-OF-CONCEPT FOR THIS NOVEL DISEASE MANAGEMENT THERAPEUTIC TOOL. IF SUCCESSFUL, THIS THERAPEUTANT CAN OFFER SIGNIFICANT ECONOMIC BENEFITS TO THE AQUACULTURE INDUSTRY INPROVIDING A SAFER THERAPY WITH LESS/NO NEGATIVE IMPACT ON THE ENVIRONMENT AND WITH BETTER REGULATORY AND CONSUMER ACCEPTANCE OF ANTIBIOTIC-FREE FARM FISH PRODUCTS. IN ADDITION, THIS TECHNOLOGY AND THERAPEUTIC APPROACH HAS APPLICATION TO OTHER FARMED ANIMALS OF AGRICULTURAL IMPORTANCE. THE OVERARCHING GOAL OF THIS PROJECT IS TO INTEGRATE TECHNOLOGIES ACROSS MULTIPLE DISCIPLINES IN DEVELOPING A SAFER DISEASE MANAGEMENT PRODUCT TO BE USED IN REARING FOOD FISH AND IN PROVIDING CONSUMERS WITH A SAFER FOOD SUPPLY.
$168,817Arkansas State University · · FY2018 · National Institute of Food and Agriculture
Phase IV Trial to Evaluate Antimicrobial Therapy of Community Acquired Pneumonia in Children - VTEU
$168,776David Bernstein · Cincinnati Childrens Hosp Med Ctr · N01 · FY2016 · AI
Longitudinal Analysis of the Fecal Microbiome and Resistome of Patients with Multidrug-Resistant Urinary Tract Infections and Predictors of Recurrence
$168,741Jennie H Kwon · Washington University · K23 · FY2021 · AI
Longitudinal Analysis of the Fecal Microbiome and Resistome of Patients with Multidrug-Resistant Urinary Tract Infections and Predictors of Recurrence
$168,741Jennie H Kwon · Washington University · K23 · FY2020 · AI
Longitudinal Analysis of the Fecal Microbiome and Resistome of Patients with Multidrug-Resistant Urinary Tract Infections and Predictors of Recurrence
$168,741Jennie H Kwon · Washington University · K23 · FY2019 · AI
Longitudinal Analysis of the Fecal Microbiome and Resistome of Patients with Multidrug-Resistant Urinary Tract Infections and Predictors of Recurrence
$168,741Jennie H Kwon · Washington University · K23 · FY2022 · AI
Cathelicidins in Skin Immunity
$168,549Veterans Medical Research Fdn/San Diego · R01 · FY2002 · AI
Antimicrobial Synergy for Carbapenem-Resistant Enterobacteriaceae
$168,480Thea Brennan-Krohn · Beth Israel Deaconess Medical Center · K08 · FY2021 · AI
Metabolic Drug Targeting in Haemophilus influenze
$168,424Genomatica, Inc. · R43 · FY2004 · AI
HTS assay development for bacterial transcription factors
$168,419Joseph Thomas Wade · Wadsworth Center · R01 · FY2013 · GM
Micro-patterned surfaces for reducing the risk of catheter-associated UTI
$168,404Shravanthi Reddy · Sharklet Technologies, Inc. · R43 · FY2009 · DK
Controlling Optical Properties of Silver Nanoclusters with DNA Scaffolds
$168,175Yolanda Aisis Small · York College · SC2 · FY2018 · GM
The molecular epidemiology of enteropathogenic (EPEC) and enteroaggregative (EAEC) Escherichia coli among adult patients in Seattle
$168,145Giannoula Tansarli · University Of Washington · K23 · FY2024 · AI
Gene silencing therapeutics for chronic infections in cystic fibrosis
$168,125David Elihu Greenberg · Ut Southwestern Medical Center · R21 · FY2014 · AI
Exploiting membrane targets to overcome antibiotic resistance
$168,043Suzanne L. Walker · Harvard Medical School · U19 · FY2024 · AI
Validation of Antimicrobial Resistance Data Analysis and Quality Control Procedures for Whole Genome Sequencing Using Commensal E. coli from Multiple Animal Species
$168,000Claire R Burbick · Washington State University · U18 · FY2018 · FD
Sepsis phenotypes at risk for infections caused by multidrug resistant Gram-negative bacilli: elucidating the impact of sepsis definition and patient case mix on prediction performance
$167,942Maria Cristina Vazquez Guillamet · Washington University · K08 · FY2020 · GM
Treatment implications of heterogeneity in acute respiratory failure risk among patients with hospital-onset sepsis
$167,832Jennifer Claire Ginestra · University Of Colorado Denver · K01 · FY2025 · HL